Hoth Therapeutics Integrates OpenAI API to Accelerate HT-KIT IND Prep with 80% KIT Suppression
Hoth Therapeutics has integrated the OpenAI API into its HT-KIT workflow to support IND-enabling preclinical data analysis, molecular modeling and regulatory filing preparation. Preclinical results show over 80% KIT mRNA reduction with tumor volume reduction by Day 8, no dose-limiting toxicities, as HT-KIT advances toward IND submission and Phase 1.
1. OpenAI API Integration
Hoth Therapeutics has embedded the OpenAI API platform into its HT-KIT development workflow to streamline preclinical data analysis, molecular modeling of KIT-driven pathways and regulatory filing preparation required for IND submission.
2. Preclinical Efficacy Data
HT-KIT preclinical studies demonstrate over 80% reduction in KIT mRNA and protein in vitro and in vivo models of systemic mastocytosis and GIST, with no dose-limiting toxicities and statistically significant tumor volume reduction by Day 8.
3. Regulatory Progress
Hoth has completed GLP-validated bioanalytical methods for pharmacokinetic and biodistribution analyses, received orphan drug designation and is advancing HT-KIT toward Investigational New Drug submission and Phase 1 clinical evaluation.